| abstract |
The present disclosure relates to, inter alia , a method of treating a patient in need of treatment with a C5 inhibitor or a method for inhibiting formation of terminal complement in a patient, comprising administering an effective amount of a C5 inhibitor, such as eculizumab or an eculizumab variant, to a patient who is or will be in compliance with vaccination with a Neisseria meningococcal Type B specific vaccine. |